Atrial Fibrillation
📧 Sign up to get email alerts when something new happens for Atrial Fibrillation.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-11-18FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Digoxin from Hikma Pharmaceuticals USA Inc., authorizing changes to the product's labeling. …
-
FDA approval · 2011-11-14FDA Approved: LANOXIN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for LANOXIN (digoxin) submitted by Advanz Pharma (US) Corp., corresponding to a labeling update …
-
FDA approval · 2011-11-14FDA Approved: LANOXIN — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for LANOXIN (digoxin) from Covis Pharma US, Inc., likely resulting in labeling updates for the produ…
-
FDA approval · 2011-11-14FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride submitted by Teva Pharmaceuticals Inc. This action finalizes changes to …
-
FDA approval · 2011-11-02FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (EXELA PHARMA SCIENCES, LLC)
FDA approved a supplemental NDA for Verapamil Hydrochloride from Exela Pharma Sciences, LLC under NDA 018925.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-10-28FDA Approved: CARTIA XT — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for CARTIA XT (diltiazem hydrochloride) under ANDA074752.
-
FDA approval · 2011-09-26FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Digoxin from Hikma Pharmaceuticals USA Inc., resulting in updated labeling for the product.
-
FDA approval · 2011-08-22FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-08-19FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (OCEANSIDE PHARMACEUTICALS)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride, allowing continued marketing of this generic p…
-
FDA approval · 2011-08-17FDA Approved: BETAPACE — Supplemental Application (Legacy Pharma USA, Inc.)
FDA approved a supplemental application for BETAPACE (sotalol hydrochloride) from Legacy Pharma USA, Inc.
-
FDA approval · 2011-08-03FDA Approved: VERAPAMIL HYDROCHLORIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved verapamil hydrochloride as an original application generic drug by Glenmark; the product is indicated for conditions treated by…
-
FDA approval · 2011-07-11FDA Approved: PROPAFENONE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for propafenone hydrochloride, enabling its generic marketing by Strides Pharma Science Limited as a…
-
FDA approval · 2011-07-11FDA Approved: TIKOSYN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TIKOSYN (dofetilide) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2011-06-21FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-04-28FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Sotalol Hydrochloride by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2011-03-11FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved the supplemental application for Multaq (dronedarone) filed by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-02-11FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-02-03FDA Approved: BETAPACE — Supplemental Application (Legacy Pharma USA, Inc.)
FDA approved a supplemental application for BETAPACE (sotalol hydrochloride) submitted by Legacy Pharma USA, Inc., resulting in updated labe…
-
FDA approval · 2011-01-31FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-01-27FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Diltiazem Hydrochloride from Teva Pharmaceuticals USA, Inc., updating the product's regulato…
-
FDA approval · 2011-01-20FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for diltiazem hydrochloride (Apotex Corp.), a generic calcium channel blocker. The approval covers t…
-
FDA approval · 2010-11-23FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
FDA's entry shows a supplemental application submission for Cardizem LA (diltiazem hydrochloride extended-release). The sponsor is Bausch He…
-
FDA approval · 2010-11-22FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental NDA for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
FDA approval · 2010-10-18FDA Approved: PROPAFENONE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approves a supplemental application for Propafenone hydrochloride from Strides Pharma Science Limited to market its generic product.
-
FDA approval · 2010-10-18FDA Approved: PROPAFENONE HYDROCHLORIDE — Original Application (Strides Pharma Science Limited)
FDA approved Propafenone hydrochloride from Strides Pharma Science Limited under an Original Application, making a generic antiarrhythmic av…